Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zomedica Pharmaceuticals Corp (NY: ZOM )

0.1589 UNCHANGED
Streaming Delayed Price Updated: 8:00 PM EDT, May 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,665
Open 0.1589
Bid (Size) 0.1463 (2)
Ask (Size) 0.1490 (24)
Prev. Close 0.1589
Today's Range 0.1589 - 0.1589
52wk Range 0.1200 - 0.2450
Shares Outstanding 979,949,668
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ZOM Stock Earnings: Zomedica Misses Revenue for Q1 2024
ZOM stock results show that Zomedica missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Zomedica Announces First Quarter 2024 Financial Results: Revenue up 14% to $6.3 Million; 66% Gross Margin, and $91 Million in Liquidity
Via ACCESSWIRE

Performance

YTD
-14.39%
-14.39%
1 Month
+12.94%
+12.94%
3 Month
+26.41%
+26.41%
6 Month
-11.48%
-11.48%
1 Year
-18.60%
-18.60%

More News

Read More
Zomedica to Present at the EF Hutton Annual Global Conference on May 15, 2024
Via ACCESSWIRE
Zomedica Corp. (NYSE American: ZOM) Featured in Coverage of the EF Hutton Annual Global Conference
Via Investor Brand Network
Zomedica Expands International Reach with CE Certification for VetGuardian(R) System
Via ACCESSWIRE
Zomedica Strengthens Market Position with New Patents Issued for its TRUFORMA(R) Diagnostic Platform
Via ACCESSWIRE
ZOM Stock Earnings: Zomedica Beats Revenue for Q4 2023
Via InvestorPlace
Zomedica to Report First Quarter 2024 Financial Results and Provide Business Update on May 9th at 4:30 p.m. ET
Via ACCESSWIRE
Zomedica to Present at the Noble Capital Markets Virtual Healthcare Conference on April 17, 2024
Via ACCESSWIRE
Zomedica Reports Record Revenue of $7.3 Million for the Fourth Quarter and $25.2 Million for the Full Year 2023, Reflecting 33% Annual Growth; 69% Gross Margin and $100.5 Million in Liquidity
Via ACCESSWIRE
Zomedica to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Monday, April 1, 2024, at 4:30 p.m. ET
Via ACCESSWIRE
Zomedica Announces Publication of Research Concluding TRUFORMA(R) Platform is More Accurate Diagnostic Test for Feline Hyperthyroidism than Chemiluminescent Immunoassay (CLIA) Platform
Via ACCESSWIRE
Earnings Scheduled For April 1, 2024
Via Benzinga
Zomedica Provides NYSE American Listing Update
Via ACCESSWIRE
Zomedica Announces Sponsorship of Educational Presentations at Fetch dvm360 Veterinary Conferences
Via ACCESSWIRE
Zomedica Announces Publication of Case Series Highlighting Success with PulseVet(R) Shock Wave Therapy for Difficult to Treat Fibrotic Myopathy in Working Dogs
Via ACCESSWIRE
Zomedica to Present at the Sidoti Small Cap Conference March 14, 2024
Via ACCESSWIRE
3 High-Reward Penny Stocks to Uncover Big Gains
Via InvestorPlace
Zomedica Announces Sponsorship of Educational Presentations at Major Veterinary Health Conferences
Via ACCESSWIRE
7 Penny Stocks to Buy on the Dip: February 2024
Via InvestorPlace
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Zomedica Shareholders Vote for the Share Consolidation (Reverse Stock Split)
Via ACCESSWIRE
Zomedica to Host Virtual Investor Day February 13 at 3:00 p.m. ET
Via ACCESSWIRE
3 Hidden-Gem Penny Stocks That Could Yield Life-Changing Wealth
Via InvestorPlace
Open Letter to Zomedica Shareholders from your Chief Executive Officer
Via ACCESSWIRE
Zomedica to Participate in the Lytham Partners 2024 Investor Select Conference
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.